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Abstract
One of the important issues in the pharmaceutical development of a semisolid preparation for dermal use is the scientific and 
experimental justification for choosing the base-carrier of active substances.
The aim of this study was to experimentally substantiate the choice of rational combination of excipients in the development 
of a semisolid dosage form with a probiotic component for use in dermatology.
Materials and methods. Hydrophilic gelling agents were used as excipients in the study: Sepiplus 400, Aristoflex AVC, Car-
bopol 934, hydroxyethylcellulose HEC, sodium alginate. Physical and chemical, pharmaco-technological and microbiological me-
thods were used to select the optimal basis. Colloidal stability was determined using a laboratory centrifuge at a speed of 6000 rpm 
for 5 min, an electronic thermometer and a water bath laboratory. Thermostability was determined in the thermostat at (40 ± 2) °C for 
24 hours. Investigation of the rheological properties of the samples was performed using a Rheolab QC (Anton Paar, Austria) rheo-
viscometer using a system of coaxial cylinders C-CC27/SS. The kinetics of water absorption of the samples were studied by dialysis 
through a semipermeable Cuprophan membrane, Type 150 pm at a temperature of (34 ± 2) °C. The number of viable lactobacilli cells 
was determined by surface seeding on Petri dishes with dense MRS medium.
Research results. The results of the study of the number of viable lactobacilli cells showed that the lowest number of viable 
cells was in sample based on HEC. Tests for thermostability and colloidal stability showed that for sample No. 5 based on sodium 
alginate, stratification was observed in the experiment, which indicates its instability. These samples were excluded. Samples on 
Sepiplus 400 and Aristoflex AVC on a set of rheological features have advantages both consumer and technological; and sample on t 
Aristoflex AVC has the best indicators of osmotic activity and the viability of cells in the dynamics for this study.
Conclusions. As a result of physical and chemical (organoleptic, colloidal and thermostability), pharmaco-technological 
(osmotic and structural and mechanical properties) and microbiological studies (number of viable lactobacilli cells) studies it was 
found that further work should be carried out with a sample based on gelling agent Aristoflex AVC, which has the most optimal 
performance in this development for a semisolid dosage form with a probiotic component for use in dermatology.
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1. Introduction
The skin is a complex barrier organ consisting of a symbiotic relationship between micro-
bial communities and host tissue through complex signals provided by innate and adaptive im-
mune systems [1]. The skin is constantly exposed to various endogenous and exogenous factors – 
physical, chemical, bacterial and fungal, which affect this balanced system, potentially leading 
to inflammatory skin conditions, including infections, allergies or autoimmune diseases [2]. The 
skin, as a link between the internal organs and the external environment, is always in contact with 
various substances and agents, including microorganisms that colonize the skin [3].
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In skin care products, probiotics can help restore the skin’s natural balance by ensuring that 
it is functioning properly and is replenished with the necessary nutrients to stay protected from 
harmful factors and fight the signs of aging and environmental damage. Probiotics are also an 
effective anti-inflammatory agent, helping to relieve redness, irritation, and skin diseases, includ-
ing acne, rosacea and dry skin [4].
Therefore, the creation of effective means of correction and protection of human normoflora 
to maintain a healthy skin microbiome today is an urgent task. 
Preliminary analysis of the literature and our own research to create a semisolid dosage 
form for dermal use, we have selected the following active ingredients: probiotic component – 
Lactobacillus strains; regenerating, anti-inflammatory, reparative component – dexpanthenol; 
moisturizing and antimicrobial component – lactic acid.
Probiotic strains of Lactobacillus plantarum 8P-A3 and Lactobacillus fermentum 90T-C4 
are classic production strains that form the basis of many domestic and foreign probiotics, mainly 
in the form of lyophilized biomass, which are used to treat dysbacteriosis of various etiologies in 
children and adults; are characterized by high antagonistic properties and specific activity and are 
safe for human use [5].
According to the literature, an adequate number of lactobacilli, which is responsible for the 
manifestation of positive mechanisms of action of these microorganisms, is 107–109 CFU (colony- 
forming units)/ml (or CFU/g) [6]. It is this range that we have focused on when creating a semisolid 
preparation for skin application.
Deviations from normal skin acidity can be the cause or consequence of many serious dis-
orders of barrier function [6]. Therefore, to enhance the antimicrobial properties of the developing 
dosage form and reduce the alkalinity of the environment, which is characteristic of dermatitis and 
acne (prevalence in the skin of an alkaline environment leads to the reproduction of bacteria ca-
pable of provoking acne [7]), lactic acid solution was administered in the preparation. It should be 
noted that lactic acid is a metabolite of the organism of the macroorganism and can be considered 
as a biologically safe product, which differs favourably from other antimicrobial substances [8]. In 
cosmetics lactic acid is used as an effective mild exfoliant and skin moisturizer, as it is part of its 
natural moisturizing factor [9]. We hypothesized that due to the physiological nature of lactic acid 
to probiotic cultures (lactic acid bacteria assimilate glycogen, breaking it down to endogenous lac-
tic acid [10]) strains of lactic acid bacteria are sufficiently resistant to its action, which will allow 
the usage of lactic acid in conjunction with probiotic cultures in one dosage form.
We also proposed the introduction of dexpanthenol, which belongs to the group of «skin» 
vitamins, as a dermatoprotector due to its regenerating, anti-inflammatory, and reparative action. 
Also, the use of dexpanthenol together with a probiotic component in one dosage form is justified 
due to the physiological needs of lactobacilli: in addition to carbohydrates, lactobacilli need for 
their development various growth factors, including pantothenic acid and its derivatives [11, 12].
The amount of dexpanthenol and lactic acid solution 80 % was selected based on the analy-
sis of semisolid preparations for the treatment of dermatological diseases and our own previous 
studies on the combined use of selected components with lactobacilli and was 4 % and 1 %, re-
spectively [13, 14].
One of the important issues in the pharmaceutical development of a semisolid preparation 
for dermal use is the scientific and experimental justification for choosing the base-carrier of active 
substances, because only the right combination of active ingredients with the base can provide the 
necessary action, appropriate technological and consumer qualities of the drug [15].
The use as an active component of living cells of probiotic cultures determines the specifi-
city of the created medicine and puts forward a number of requirements for the preparation of the 
dosage form. The basis and parameters of production of living biotherapeutic drugs, first of all, 
should ensure the viability of cells and the preservation of their probiotic activity [16]. Therefore, 
the main criterion for the selection of excipients in the semisolid dosage form being developed is to 
maintain the survival of lactobacilli and ensure the stability of the drug.
Another factor influencing the choice of auxiliary components for a drug with a probiotic 
component is the content in the dosage form of water, which leads to hydration of lyophilized 
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biomass and cell proliferation in the composition, which, in turn, will contribute to the instability 
of the dosage form. When choosing the basis, it was taken into account that hydrophilic bases, in 
particular macrogols, have a hyperosmolar effect, which leads to dehydration of the cell and its 
osmotic shock [17]. In this case, these characteristics of hydrophilic bases limit their use. 
That is why some researchers suggest the use of lipophilic ointment bases in the develop-
ment of semisolid dosage forms with a probiotic component. But in the development of semisolid 
preparations should take into account the main pathogenetic factors whose interaction contributes 
to the manifestation of infectious and inflammatory diseases of the skin, including acne: sebaceous 
gland production, changes in keratinization, colonization of pathogenic microorganisms follicles 
and the release of inflammatory mediators [18]. That is, in such dermatological diseases, the in-
crease in the amount of sebum, in which the skin surface becomes oily makes it inappropriate to 
use purely lipophilic ointment or cream bases. This can lead to overload of fatty components of 
already oily skin, pH shift to the alkaline side, clogging of pores and lack of positive effect of the 
active components of the drug. Also, when using lipophilic bases, another problematic question 
arises - how easily microorganisms can be released from the oil base applied to the skin and thus 
become metabolically active, sufficient to provide the necessary probiotic effects.
We consider it possible to overcome these shortcomings by developing a semisolid dosage 
form on an emulgel basis. Such base is a stable heterogeneous system and has the advantages of 
emulsion and gel [19]. The formation of gels is associated with the emergence and strengthening 
of bonds between macromolecules of polymers with the formation of a spatial network that holds 
almost the entire volume of the solvent, which is a significant factor in this development. The intro-
duction of the probiotic component into the composition of the drug should be carried out through 
the oil phase, thereby stabilizing the lactobacilli. That is, when using hydrophilic solvents, the 
creation of an oil phase in which lactobacilli are incorporated will protect the cells from the action 
of moisture and a certain hyperosmolar action of the base’s components.
Thus, the aim of our study was to experimentally substantiate the choice of rational combi-
nation of excipients in the development of a semisolid dosage form with a probiotic component for 
use in dermatology.
2. Material and methods
The research was performed from 2019 to 2021 at the Department of Biotechnology of the 
National University of Pharmacy. Hydrophilic gelling agents were used as excipients in the study: 
acrylic acid derivatives – Sepiplus 400 (polyacrylate-13-polyisobutene-polysorbate-20, «Seppic», 
France), Aristoflex AVC (copolymer of acrylamidopropylpropanesulfonic acid and vinylpyrro-
lidone, «Clariant Surfactants», Switzerland), Carbopol 934 (polymer of acrylic acid with allyl 
sucrose or allyl pentaerythritol, «Lubrizol», USA), cellulose derivative – hydroxyethylcellulose 
HEC («Ashland», Netherlands), polysaccharide – sodium alginate («BASF», Germany). The selec-
ted gelling agents have a wide working range of pH with the possibility of its adjustment, which 
is an advantage in this development due to the content in the composition of lactic acid, allow to 
obtain semisolid dosage forms without the use of high temperatures, which is important when 
administering a probiotic component, are compatible with many substances. The concentration of 
gelling agents in this series of studies was 2 %.
The results of our previous studies were used [19] in the preparation of emulgel samples. The 
introduction of the probiotic component in the form of lyophilized biomass of lactobacilli into the 
soft dosage form being developed, it is advisable to carry out through the oil phase – vegetable oil, 
by pre-dissolving it in polysorbate-80. This method causes high survival rates of lactobacilli, system 
stability and uniform particle distribution in the oil phase. Propylene glycol (10 %), in which dex-
panthenol was dissolved, was added to all samples to give the semisolid dosage form high consumer 
properties and to prevent drying. The lactic acid solution was introduced into the hydrophilic phase.
Emulgel samples were prepared in common approaches according to the specificity of 
gelling agents, given that Sepiplus 400 and Aristoflex AVC are pre-neutralized substances and 
have emulsifying ability, HEC requires control of the rate of addition in order to ensure the com-
pleteness of the wettability of the particles, Carbopol 934 – neutralization (using a solution of 
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triethanolamine) and together with HEC – the presence of an emulsifier, the function of which was 
performed by polysorbate-80.
Based on our goal, modern physical and chemical, pharmaco-technological and microbio-
logical methods were used to select the optimal basis. Organoleptic parameters, thermal and colloi-
dal stability, pH and structural and mechanical properties of the studied samples were determined. 
Colloidal stability was determined using a OPN-8 laboratory centrifuge at the rate of 6000 rpm 
for 5 min, an TP-101 electronic thermometer and a WB-4 water bath laboratory. Thermostability 
was determined by keeping the samples first in a TC 1/80SPU thermostat at (40 ± 2) °C, then in 
a refrigerator at (10 ± 2) °C and at room temperature, in the absence of delamination.
Investigation of the rheological (structural and mechanical) properties of the samples was 
performed using a Rheolab QC rheoviscometer (Anton Paar, Austria) using a system of coaxial 
cylinders C-CC27/SS. The Rheolab QC rheometer is equipped with RheoPlus software, which 
allows to set the necessary experimental conditions (range of the gradient of the shear rate, the 
number of measuring points and the measurement time of one point). Rheological measurements 
were performed in three stages:
a) a linear increase in the gradient of the shear rate from 2 s–1 to 300 s–1 with 105 measuring 
points and the duration of the measurement point 1 s;
b) a constant shift at a shear rate of 300 s–1, one measuring point lasting 1 s;
c) a linear decrease in the gradient of the shear rate from 300 s–1 to 2 s–1 with 105 measure-
ment points and the measurement duration of the point 1 s.
The study was performed at 25 ± 0.5 °C, the duration of thermostating of each sample was 
30 minutes.
The flow point (boundary) was calculated using the software using a mathematical mo-
del of the Casson rheological flow. The coefficient of dynamic rarefaction (flow) was determined 
at shear rates of 2.0 and 10.6 s–1, corresponding to the shear rate of the palm when distributing 
the semisolid dosage form on the surface and the viscosity of the system at shear rates of 27.8 
and 151 s–1 corresponding to the speeds during processing in the process of its manufacture. Based 
on the results obtained, the values of the coefficients of dynamic rarefaction of the system were 
calculated according to the formulas:
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Kd1, Kd2 – dynamic rarefaction coefficients; η − structural viscosity at appropriate shear rates, Pa∙s.
The calculation of mechanical stability (MS) was performed at a shear rate of 2.0 s–1, the 







The kinetics of water absorption by the studied samples were studied by dialysis through 
a semipermeable Cuprophan membrane, Type 150 pm at a temperature of (34 ± 2) °C, maintained 
by a thermostat. The XSP-128 ULAB biological microscope was used to visually examine the 
homogeneity of the samples.
The number of viable lactobacilli cells was determined by surface seeding on Petri dishes 
with dense MRS medium. 15 to 20 ml of molten MRS agar with a temperature of about 45 °C 
was added to each Petri dish. After solidification of the medium and drying in a laminar stream 
of sterile air, a precisely measured volume (0.1 ml) of the prepared test sample was distributed 
over its surface. The cultures were incubated in a thermostat for 3 days at a constant tempera-
ture (37 ± 1) °С. The arithmetic means of the number of colonies of lactobacilli grown on nutrient 
medium was calculated and the number of CFU in 1 ml of sample was determined. To control and 
identify lactobacilli, the morphology of colonies and cells was observed under microscopy (bio-
logical microscope XSP-128 ULAB). The microorganisms corresponded to the taxonomic charac-
teristics – the morphology of the colonies on the media and the morphology of the cells under 
microscopy were typical for lactobacilli.
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3. Research results 
In order to select the optimal type of gelling agent, we prepared each sample according 
to the method recommended for a particular polymer, with the introduction of selected active 
substances and determined their physical and chemical, pharmaco-technological and microbiolo-
gical parameters.
The critical parameter of the semisolid dosage form with the probiotic component is the 
viability of lactobacilli cells, so the first step in our study was to determine the number of viable 
cells in each sample (Table 1).
Table 1 
The number of viable lactobacilli cells in the test samples
Sample Gelling agent The number of viable cells*, CFU/ml
No. 1 Sepiplus 400 (3.05 ± 0.02)∙107
No. 2 Carbopol 934 (4.54 ± 0.01)∙107
No. 3 Aristoflex AVC (3.80 ± 0.02)∙107
No. 4 HEC (2.11 ± 0.03)∙106
No. 5 Sodium alginate (2.93 ± 0.01)∙107
Note: * – the permissible value of the quality indicator of the drug under development – not less than 107 CFU/ml, n = 5; P = 95 %; 
(M ± m) – confidence interval
The results of this series of experiments showed that the lowest number of viable cells was in 
sample No. 4 based on HEC and was (1.11 ± 0.03)⋅106 CFU in 1 ml of sample, which is less than the 
allowable value of the quality indicator of the drug «number of viable cells». Therefore, this sample 
was excluded from further studies.
The next step was the analysis of organoleptic and physical and chemical parameters of the 
experimental samples (Table 2).
Table 2 













1 Description and homoge-neity
Homogeneous mass  
of white color, with  
a small number of air 
bubbles, with a slight 
specific odor, sticky, 
low-viscosity
Homogeneous mass 
of white color, with 
a large number of air 
bubbles, with a slight 
specific odor, sticky, 
not viscous
Homogeneous mass  
of white color, with  
a small number of air 
bubbles, with a slight 
specific odor, sticky, 
non-viscous
Homogeneous after 
mixing mass of white 
color, with a slight 
specific odor, non-
sticky, low-viscosity
2 Thermal stability stable stable stable unstable
3 Colloidal stability stable stable stable unstable
All samples are homogeneous in consistency, have the same color and specific odor. Sam-
ples No. 2 and No. 3 with the addition of Carbopol 934 and Aristoflex AVC are sticky to the touch, 
which can help the gel to adhere to the skin. Sample No. 1 is inferior in density to others, sticky, 
capable of stretching, elongated without breaking. Tests for thermal stability and colloidal stability 
showed that for sample No. 5 based on sodium alginate, stratification was observed in the experi-
ment, which indicates its instability. This led to the exclusion of this sample from further research.
Developing the composition of semisolid drugs, much attention is paid to the study of their 
rheological properties. This is due to the fact that with the help of these indicators the composition 
of excipients is substantiated to ensure primarily consumer indicators, the choice of parameters of 
the technological process of production is carried out, storage stability is investigated, etc.
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The study of rheological properties showed that samples No. 1, No. 2, No. 3 are heteroge-
neous emulsion systems, which are stabilized by the use of surfactants aimed at reducing the surface 
tension at the phase boundary, and by using structurants in the hydrophilic and lyophilic phase.
Rheograms of the flow of samples are shown in Fig. 1, 2, which shows that all samples show 
a plastic type of flow, because their flow begins after some shear stress. The numerical interval 
from the origin to the flow of the system quantifies the elastic properties of the samples, i.e., the 
systems behave as a viscoelastic solid. Under the action of increasing shear force, the systems begin 
to flow, during the flow of the studied samples, the viscosity decreases, which is characteristic of 
non-Newtonian fluids. 
Fig. 1. Dependence of shear stress (τ, Pa) on the shear rate gradient (γ, 1/s) of the studied samples
Fig. 2. Dependence of structural viscosity (η, mPa∙s) on the shear rate gradient  
of the studied samples
The profile of rheograms clearly shows the dependence of rheological parameters on the 
type of dispersed system, samples No. 1, No. 2, No. 3 with Sepiplus 400, Carbopol 934 and Aris-
toflex AVC, respectively, are highly thixotropic systems, the recovery of such systems coincides 
in time with their rarefaction, because the ascending and descending flow curves are practically 
superimposed on each other.
Tables 3, 4 show the values of shear stress and structural (dynamic) viscosity of the samples 













No. 1 Sepiplus 400
No. 3 Aristoflex AVC
















No. 1 Sepiplus 400
No. 3 Aristoflex AVC
No. 2 Carbopol 934
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Table 3









Shear stress (τ, Pa) with increasing/decreasing shear speed gradient (γ, s–1)
2.0 98.1/94.8 62.3/59.9 127/124
4.87 122/118 80.5/71.3 145/145
10.6 149/147 97.5/85.4 170/171
19.2 178/175 114/100 196/197
27.8 200/197 125/111 216/217
151 358/360 199/194 356/359
300 478/478 251/251 454/453
Structural (dynamic) viscosity (η, Pa∙s) with increasing/decreasing shear speed gradient (γ, s–1)
2.0 49/47.4 31.5/30 63.2/61.9
4.87 25/24.4 16.5/14.7 29.9/4.87
10.6 14.1/13.8 9.2/8.06 16.1/16.1
19.2 9.29/9.12 5.93/5.21 10.2/10.3
27.8 7.2/7.08 4.52/4.01 7.76/7.8
151 2.37/2.39 1.32/1.28 2.35/2.37
300 1.59/1.63 0.83/0.83 1.51/1.51
Table 4
Calculated structural and mechanical parameters of the samples





The flow limit by Casson I τ0, Ра 103.4 68.9 131.87
Coefficient of dynamic rarefaction Kd1, % 71.22 70.79 73.52
Coefficient of dynamic rarefaction Kd2, % 67.08 70.79 67.91
Mechanical stability МС with γ 2.0–1 1.04 1.04 0.96
Sample No. 2 with carbomer in the composition, has the lowest structural and mechanical 
properties, the system is easily liquefied under the action of low mechanical factors, which can be 
a critical parameter in scaling the production technology. Samples No. 1 Sepiplus 400 and No. 3 
Aristoflex AVC on a set of rheological features have advantages both consumer and technological. 
Such systems are easy to apply and distribute on the skin surface, stable under the action of ma-
chining during production, used structurers Sepiplus 400 and Aristoflex AVC provide subjective 
cosmetic benefits to the developed samples.
Components used as components of bases are able to absorb water and have certain osmotic 
properties. It is known that the osmotic effect of hydrophilic bases can last 18 hours or more. This 
may prolong the action of the drug, but, as mentioned above, the same effect can lead to dehydra-
tion of skin cells and probiotics, which are the active ingredient of the drug. Therefore, the next step 
was to study the osmotic activity of the experimental samples (Fig. 3). 
The study showed that during the experiment, the test samples absorb water gradually – 
after 1 hour the mass of water absorbed for samples No. 1, No. 2 and No. 3 is 30 %, 27.4 % and 
26.2 %, respectively, after 2 hours – 34.1 %, 32.1 % and 30.4 %, after 3 hours – 38.5 %, 38 %, 
35.1 %. Further study of the osmotic activity of the samples showed that the experimental samples 
No. 1 and No. 3 absorb water for 8 hours, and the sample No. 2 – for 10 hours. Then the samples 
reach equilibrium, with the lowest indicator of the level of absorption shows the sample No. 3 – 
62.1 %, samples No. 1 and No. 2 have indicators of 73.4 % and 80 %, respectively.
Due to the need to preserve the survival of lactobacilli in the base, the next step was to 
determine the viability of cells in the experimental samples in the dynamics for 3 months (Fig. 4).
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Fig. 3. Osmotic activity of experimental samples
Fig. 4. Logarithm of the number of viable lactobacilli cells in the test samples
Previous studies have shown that in freshly prepared samples No. 1, No. 2 and No. 3 
with the same initial dose of lactobacilli, the logarithm of the number of viable cells was 7.301, 
7.544 and 7.447, respectively, i.e., the highest indicator was the sample based on Carbopol 934, 
the lowest – based on Sepіplus 400. But the determination of the number of viable cells in the 
dynamics for 3 months showed better characteristics for the sample based on Aristoflex AVC, the 
logarithm of the number of cells in 1 ml of the sample was 7.342 and was higher than for the sam-
ples based on Carbopol 934 and Sepiplus 400 (7.041 and 6.903 respectively).
Thus, we focused on sample No. 3 based on Aristoflex AVC, which in this development has 
the best performance for a drug with a probiotic for use in dermatology.
4. Discussion
The skin microflora plays an important role in maintaining homeostasis and the state of 
local immunity. Current information on the state of the microbiome of healthy skin has led to the 
conclusion that detailing the composition of the microbiome in the sebaceous glands is normal and 
in pathology expands information about the pathogenesis of acne, seborrheic dermatitis and rosacea. 
Features of the microbiome of dry skin can be the basis for studying the pathogenesis of psoriasis, 
and areas with high humidity – to study the pathogenesis of atopic dermatitis [2]. Numerous studies 
show the need to maintain the skin microbiome [2, 3]. Moreover, the violation of the skin micro-
biome can be a consequence of infectious and inflammatory dermatoses and their treatment with 
antimicrobials, and the cause, as the reduction of the microbiome of this ecosystem normally leads 
to the activation of opportunistic pathogens and, consequently, to infectious disease. And treatment 
of dermatoses exclusively with antimicrobial and anti-inflammatory drugs leads to long-term, 
often ineffective, treatment with frequent recurrences [20].
Therefore, for the treatment of this pathology, we have chosen a semisold dosage form for 
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normal skin microbiocenosis and at the same time prevent or treat dermatological inflammatory 
and infectious diseases. That is, the product under development can be used as a primary treatment 
or, depending on the condition of the disease, as a concomitant during treatment and after to restore 
the skin, or as a prophylactic for skin types prone to these dermatological diseases.
In the studies, we prepared samples of a semisolid drug in the form of an emulgel based on 
Aristoflex AVC, Carbopol 934, Sepiplus 400, HEC and sodium alginate with active ingredients: 
lyophilized biomass of lactobacilli, dexpanthenol and lactic acid.
As a result of physical and chemical (organoleptic, colloidal and thermostability), 
pharmaco-technological (osmotic and structural and mechanical properties) and microbiological 
studies (number of viable lactobacilli cells) studies it was found that further work should be car-
ried out with a sample based on gelling agent Aristoflex AVC, which has the most optimal per-
formance in this development for a semisolid dosage form with a probiotic component for use 
in dermatology.
Study limitations. Concentration of gelling agent in these studies was 2 %, and it needs to 
be clarified among the range of possible concentrations.
Prospects for further research. The next step will be a pharmacological study of the ad-
justed emulgel composition and determine its stability during storage.
5. Conclusions
The criteria for selection of excipients in the creation of a semisolid dosage form with 
a probiotic component for dermatology were determined.
The expediency of creating a new drug with a probiotic in the form of an emulgel has been 
proved. The influence of gelling agents in the emulgel on the viability of lactobacilli cells, orga-
noleptic and physicochemical parameters, on the rheological characteristics and on the absorption 
properties of the samples was studied.
Based on physical and chemical, pharmaco-technological and microbiological studies the ra-
tional composition of excipients in the composition of a new drug under the conditional name «Pro-
bioskin» was selected. According to the set of indicators, it is rational to use Aristoflex AVC as 
a gelling agent, which in this development is the most optimal for the drug for dermal application 
for the treatment and prevention of dermatological diseases.
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